これは2022-11-28 05:37:54 UTCで公開された古いバージョンです。最新バージョンをお読みください。
プレプリント / バージョン2

Association analysis between type 2 diabetes and the gut microbiota: a community-based cross-sectional study in Japan

##article.authors##

  • Nagashima, Koji Department of Reseach & Development, TechnoSuruga Laboratory Co., Ltd.
  • Takayoshi Hisada Department of Reseach & Development, TechnoSuruga Laboratory Co., Ltd.
  • Jun Mochizuki Department of Research & Development, TechnoSuruga Laboratory Co., Ltd.
  • Tatsuya Mikami Innovation Center for Health Promotion, Graduate School of Medicine, Hirosaki University
  • Yoshinori Tamada Innovation Center for Health Promotion, Graduate School of Medicine, Hirosaki University
  • Shigeyuki Nakaji Innovation Center for Health Promotion, Graduate School of Medicine, Hirosaki University

DOI:

https://doi.org/10.51094/jxiv.105

キーワード:

gut microbiota、 type 2 diabetes、 Lactobacillales、 community-based cross-sectional study

抄録

There are a few studies on the association between type 2 diabetes (T2D) and the gut microbiota but no community-based cross-sectional study. In the Iwaki Health Promotion Project (Hirosaki, Japan), we surveyed medical information and lifestyle and analyzed the gut microbiota using the terminal restriction fragment length polymorphism technique or next-generation sequencing. Based on these data, multivariable logistic regression analysis was performed with or without T2D as the dependent variable. Consequently, it was suggested that the Lactobacillales population in the gut microbiota was positively associated with T2D, consistent with the results of case-control studies.

ダウンロード *前日までの集計結果を表示します

ダウンロード実績データは、公開の翌日以降に作成されます。

引用文献

(1) Wang X, Zhang A, Miao J, Sun H, Yan G, Fang-fang Wu F, Wang X. 2018. Gut microbiota as important modulator of metabolism in health and disease. RSC Adv 8: 42380-42389.

(2) Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS. Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. 2010. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5: e9085.

(3) Sasaki M, Ogasawara N, Funaki Y, Mizuno M, Iida A, Goto C, Koikeda S, Kasugai K, Joh T. 2013. Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study. BMC Gastroenterol 13: 81.

(4) Karlsson F, Tremaroli V, Nookaew I. Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. 2013. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498: 99-103.

(5) Remely M, Dworzak S, Hippe B, Zwielehner J, Aumüller E, Brath H, Haslberger A. 2013. Abundance and diversity of microbiota in type 2 diabetes and obesity. J Diabetes Metab 4: 253.

(6) Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, Komiya K, Kawaguchi M, Shimizu T, Ogihara T, Tamura Y, Sakurai Y, Yamamoto R, Mita T, Fujitani Y, Fukuda H, Nomoto K, Takahashi T, Asahara T, Hirose T, Nagata S, Yamashiro Y, Watada H. 2014. Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care 37: 2343-2350.

(7) Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015; 38: 159-165.

(8) Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmirid F, Mehrtashe A, Amirmozafari N. 2017. Comparison of gut microbiota in adult patients with type 2 diabetes. Microbial Pathogenesis 111: 362-369.

(9) Adachi K, Sugiyama T, Yamaguchi Y, Tamura Y, Izawa S, Hijikata Y, Ebi M, Funaki Y, Ogasawara N, Goto C, Sasaki M, Kasugai K. 2019. Gut microbiota disorders cause type 2 diabetes mellitus and homeostatic disturbances in gut-related metabolism in Japanese subjects. J Clin Biochem Nutr 64: 231-238.

(10) Hashimoto Y, Hamaguchi M, Kaji A, Sakai R, Osaka T, Inoue R, Kashiwagi S, Mizushima K, Uchiyama K, Takagi T, Naito Y, Fukui M. 2020. Intake of sucrose affects gut dysbiosis in patients with type 2 diabetes. J Diabetes Investig 11:1623-1634.

(11) Nakaji S, Ihara K, Sawada K, Parodi S, Umeda T, Takahashi T, Murashita K, Kurauchi S, Tokuda I. 2021. Social innovation for life expectancy extension utilizing a platform-centered system used in the Iwaki health promotion project: A protocol paper. SAGE Open Medicine 9: 1–13.

(12) Nagashima K, Hisada T, Sato M, Mochizuki J. 2003. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 69: 1251-62.

(13) Nagashima K, Mochizuki J, Hisada T, Suzuki S, Shimomura K. 2006. Phylogenetic analysis of 16S ribosomal RNA gene sequences from human fecal microbiota and improved utility of terminal restriction fragment length polymorphism profiling. Biosci Microflora 25: 99-107.

(14) Takahashi S, Tomita J, Nishioka K, Hisada T, Nishijima M. 2014. Development of a prokaryotic universal primer for simultaneous analysis of bacteria and archaea using next-generation sequencing. PLoS ONE 9: e105592.

(15) Hisada T, Endoh K, Kuriki K. Inter- and intra-individual variations in seasonal and daily stabilities of the human gut microbiota in Japanese. 2015. Arch Microbiol 197: 919-934.

(16) Kettle H, Louis P, Holtrop G, Duncan SH, Flint HJ. 2015. Modelling the emergent dynamics and major metabolites of the human colonic microbiota. Environ Microbiol 17: 1615-1630.

(17) Morita N, Umemoto E, Fujita S, Hayashi A, Kikuta J, Kimura I, Haneda T, Imai T, Inoue A, Mimuro H, Maeda Y, Kayama H, Okumura R, Aoki J, Okada N, Kida T, Ishii M, Nabeshima R, Takeda K. 2019. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. Nature 566: 110-114.

(18) Kim M, Galan C, Hill AA, Wu W, Fehlner-Peach H, Song HW, Schady D, Bettini ML, Simpson KW, Longman RS, Littman DR, Diehl GE. 2018. Critical Role for the Microbiota in CX3CR1+Intestinal Mononuclear Phagocyte Regulation of Intestinal T Cell Responses. Immunity 49: 151-163.

(19) Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nature Rev Immunol. 11: 98-107.

(20) Shin AS, Gao X, Bohm M, Lin H, Gupta A, Nelson DE, Toh E, Teagarden S, Siwiec R, Dong Q, Wo JM. 2019. Characterization of proximal small intestinal microbiota in patients with suspected small intestinal bacterial overgrowth: A cross-sectional study. Clin Transl Gastroenterol 10:e00073.

(21) Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, Wang HH, Abrams JA. 2015. Proton pump inhibitors alters specific taxa in the human gastrointestinal microbiome: A crossover trial. Gastroenterology 149: 883-885.

(22) Jackson MA, Goodrich JK, Maxan M, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ. 2016. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65: 749-756.

(23) Otsuka T, Sugimoto M, Inoue R, Ohno M. 2017. Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut 66: 1723-1725.

(24) Yuan J, He Q, Nguyen LH, Wong MCS, Huang J, Yu Y, Xia B, Tang Y, He Y, Zhang C. 2012. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 70: 1070–1077.

(25) Ciardullo S, Rea F, Savaré L, Morabito G, Perseghin G, Corrao G. 2022. Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results from a large population-based nested case-control study. J Clin Endocrinol Metab 107: e2671–e2679.

(26) Maeda T, Miki S, Morihara N, Kagawa Y. 2019. Aged garlic extract ameliorate fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance. Exp Ther Med 18: 857-866.

ダウンロード

公開済


投稿日時: 2022-06-27 01:54:04 UTC

公開日時: 2022-06-28 09:35:04 UTC — 2022-11-28 05:37:54 UTCに更新

バージョン

改版理由

1. A reference to the Iwaki Health Promotion Project and its UMIN ID was added (lines 42-43). 2. Two references to the association of proton pump inhibitors with T2D were added. Along with it, the text was revised (lines 141-146). 3. A new table named as Table 2 was constructed by combining a part of data in Table 3 and additional data. Along with it, old Table 2 was renamed as Table 3 and old Table 3 was deleted. 4. Table 1 was corrected for the number of subjects because of exclusion of the subjects with healed T2D and those with missing data. 5. Table 3 was corrected for erroneous descriptions, that is, mix-up between B-7 and B-8 in the column “Bacterial functional groups” and for some omissions in the column “OTUs in T-RFLP”. Along with it, conversion equations were partially corrected (lines 71-82).
研究分野
生物学・生命科学・基礎医学

ライセンス

Copyright（c）2022 Nagashima, Koji
Takayoshi Hisada
Jun Mochizuki
Tatsuya Mikami
Yoshinori Tamada
Shigeyuki Nakaji

Creative Commons License

この作品は、Creative Commons Attribution-NoDerivatives 4.0 International Licenseの下でライセンスされています。